title: [ASBMR 2010 report. Meeting report on the ASBMR. Obstacles in medicine for osteoporosis].
abstract: The 32nd ASBMR meeting had been held in Toronto, Ontario, Canada from October 15th to 19th 2010. In clinical session, there were several reports as to novel medicine for osteoporosis and atypical femoral fracture as an adverse event of bisphosphonates. Furthermore, relationship between bone and brain attracted great attention in basic science.
authors.affiliation: Department of Rheumatosurgery, Osaka City University Medical School.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Koike
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001842:Bone and Bones / Q000378:metabolism*; D056657:Cathepsin K / Q000037:antagonists & inhibitors; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use*; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005264:Femoral Fractures / Q000209:etiology; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D054328:Proton Pump Inhibitors / Q000009:adverse effects; D053245:RANK Ligand / Q000627:therapeutic use; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects; D012955:Societies, Medical; D014807:Vitamin D / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D056657:Cathepsin K; D000069448:Denosumab; D004164:Diphosphonates; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D053245:RANK Ligand; D017367:Selective Serotonin Reuptake Inhibitors; D014807:Vitamin D; C547512:eldecalcitol